Health Condition 1: D508- Other iron deficiency anemias
Conditions
Interventions
Intervention1: Drakshasava(Bhaisajyaratnavali,Arsorog
adhikara: 170-174
AFI Part II
: Dose : 20 ml twice daily
Dosage form: Asava
Route of Administration: Oral
Frequency:Twice a day after meals
Anupana: Equal amount of luke warm water
Total duration of therapy : 12 we
Sponsors
Central council for research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex aged between 18 to 50 years. 2. IDA documented by hematologic indices. I. Hb 8gm-10gm. % II. S.Ferritin III. TIBC >450mcg/dL IV. S.Iron V. MCV 46fL VII. Reticulocyte count (Among these the first 3 are the essential criteria for inclusion) 3. Willing and able to participate for 112 days
Exclusion criteria
Exclusion criteria: 1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites. 2. History or evidence of intestinal malabsorption 3. Major co-morbidity such as a CAD,DM,Malignancies and Auto immune disorders apparent on history, physical examination, or laboratory tests 4. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests. 5. Liver enzymes, AST/ALT > 2 x the upper limit; serum creatinine more than the upper limit. 6. Patients on prolonged ( > 6 weeks) medication that may have an influence on the outcome of the study 7. Patients suffering from Hypothyroidism or Hyperthyroidism. 8. Patients who are already on iron pills for Iron deficiency Anaemia. 9. Other medical or social factors at discretion of treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Any changes in the peripheral blood hemoglobin concentration at 0, 4, 8, and 12 weeks and end of 16th weekTimepoint: from base line to end of 4th, 8th, 12th and 16th week | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Serum ferritin level 2. Serum iron level 3.TIBC level 4. MCV level 5.Reticulocyte count 6. Red blood cell count 7. Any adverse events Timepoint: from base line to end of 4th, 8th, 12th and 16th week | — |
Countries
India
Contacts
Public ContactDr Indu P P
M.S. Regional Ayurveda Research Institute for Endocrine Disorders
Outcome results
None listed